To scroll text in this page

Global Navigation
Global Navigation end

About Astellas

Start of the main text

2017 News Releases

About RSS

Astellas Terminates Agreement with UMN Pharma for Cell Culture Based Influenza Vaccine Programs

January 10, 2017

Tokyo, January 10, 2017 - Astellas Pharma Inc. (TSE:4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) announced that it exercised its right to terminate the agreement executed as of September 21, 2010 between Astellas and UMN Pharma Inc. (TSE:4585, Chairman & CEO: Tatsuyoshi Hirano, “UMN Pharma”) for the co-development and Astellas’ exclusive commercialization of ASP7374 and ASP7373, the cell culture based influenza vaccine programs in Japan.


Upon the effective date of termination, Astellas will return to UMN Pharma all rights granted under the agreement. Astellas will withdraw the application for marketing approval of ASP7374 and discontinue the development of ASP7373.


Astellas will recognize the impairment losses for other intangible assets of 4 billion yen in the first nine months of the fiscal year ending March 31, 2017. Astellas is still reviewing the other impact on its financial results.




Printer-friendly version

Main Text end
Local Navigation
Local Navigation end
Related Links